Trials / Terminated
TerminatedNCT01910870
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- Centre Jean Perrin · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cisplatin | 25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks |
| DRUG | Metronomic Cyclophosphamide | 150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks |
Timeline
- Start date
- 2013-07-01
- Primary completion
- 2016-09-01
- Completion
- 2016-09-01
- First posted
- 2013-07-30
- Last updated
- 2018-05-18
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT01910870. Inclusion in this directory is not an endorsement.